TG Therapeutics price target lowered to $84 from $89 at H.C. Wainwright H.C. Wainwright analyst Edward White lowered the firm's price target on TG Therapeutics to $84 from $89 and keeps a Buy rating on the shares. Ukoniq revenue were lower than expected in Q2, White tells investors in a research note. The analyst believes gaining access to customers due to Covid could remain a challenge into 2022.Our Take: "This is still our favorite pick. Today's steep decline is a huge overreaction. Longer-term this company's best asset is their MS drug, which will achieve blockbuster status after approval. This sell-off in the longer run is a buying opportunity. The slower than expected roll out for Ukoniq due to Covid is just a distraction from the real story here. It is what happens in biotech land when short-term traders get impatient."Trade Idea: Buy 2022/23 calls. $TGTX, TG Therapeutics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .